# BPC-157 TB-500 Latest Research (2024-2026): Reviews and the Human-Data Gap > BPC-157 TB-500 latest research, 2024-2026: a 2025 systematic review of BPC-157 (36 studies, 1 human), a 2026 Sports Medicine review of unapproved peptides, and why none studied the combination. The most defensible recent literature is review-level — and it bounds the blend honestly: promising animal data, scarce human safety data, and no controlled combination study. ## The 2024-2026 reviews of the blend's constituents BPC-157 TB-500 latest research, across 2024-2026, is dominated by review-level work on the individual constituents — there is still no primary study of the combination. Three reviews anchor the current picture. A 2025 HSS Journal systematic review of BPC-157 in orthopaedic sports medicine included 36 studies (35 preclinical, only 1 human — a 12-patient retrospective intra-articular knee-pain report), found no clinical safety data, and graded the evidence level IV-V; it makes no mention of TB-500 or any combination [9]. A 2026 Sports Medicine narrative review of approved and unapproved musculoskeletal peptides lists both BPC-157 and TB-500/Thymosin Beta-4, and concludes that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [10]. A 2025 Current Reviews in Musculoskeletal Medicine narrative review concludes that human data for BPC-157 are extremely limited — three pilot studies — and that it should be considered investigational and used with caution given non-regulated availability [12]. These are the [2024-2026 reviews of the blend's constituents](/recent-research). Read together, they describe a promising preclinical signal bounded by a hard evidence ceiling. ## The newest single-compound studies Beyond the reviews, the freshest primary work remains single-compound and preclinical. A 2025 rat study reported BPC-157 as therapy after surgical detachment of the quadriceps muscle from its attachments, supporting muscle-to-bone reattachment healing [11]. A 2025 rat study reported BPC-157 protected liver, kidney, and lung against distant-organ damage in experimental lower-extremity ischemia-reperfusion injury [13]. A 2025 literature-and-patent review surveyed BPC-157's multifunctionality and possible medical applications [14], and a 2024 review surveyed its pleiotropic activity and possible relations with neurotransmitter signaling [15]. None of these studied TB-500 or the combination. Two standing caveats temper how this body of work should be read. First, a large share of the BPC-157 foundational literature comes from a single research group, which newer reviews explicitly flag as an independent-replication question [12]. Second, the TB-500 side of the blend leans heavily on full-length Thymosin Beta-4 data — the 7-mer fragment sold as TB-500 has zero completed controlled human trials of its own [4]. The recent literature does not close either gap. ## Where the recovery narrative is tempered Not every result points one way, and the honest reading includes the negative ones. In dystrophin-deficient mdx mice, chronic Thymosin Beta-4 (150 μg twice weekly intraperitoneally for 6 months) increased the number of regenerating muscle fibers but did not improve strength, cardiac function, or fibrosis [5]. And the rat embolic-stroke dose-response was non-monotonic: an 18 mg/kg dose gave no benefit over the modeled optimum near 3.75 mg/kg [7]. Both findings undercut the "more is better" loading logic that circulates around the blend, and neither is a combination result — they are single-compound, animal-model data on the TB-500 leg's parent protein. ## Human clinical evidence and the data gap Here is the [human clinical evidence and the data gap](/recent-research) stated plainly. There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication. Human data exist only for the individual constituents, and are themselves thin. BPC-157 has three small pilot studies: a 2-person IV safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot [16]. "TB-500" human data are for full-length Thymosin Beta-4, not the 7-mer — a Phase 1 IV safety and PK study in 40 volunteers, a 2021 first-in-human study in 84 volunteers, and topical ophthalmic trials [16]. For why that absence matters mechanistically, see [the synergy claim and the evidence gap](/research). --- Two peptides indexed as one data store — BPC-157 and TB-500 each filed under its own studies and its own 503A status, the synergy entry kept empty because no controlled combination trial exists; an editorial archive, not a clinic, not a vendor, not a prescription.